Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC).
| Image |  |
|---|---|
| Description | scientific article published in 2022 |
| Author/s |
author: Emmanuel S. Antonarakis |
| Publication date | June 1, 2022 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |